Drug Trial Radar · NCT07748403
A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Nov 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Prime Medicine, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, biological activity, and initial efficacy of PM577a, an investigational Prime Editing therapy, in adults and adolescents with Wilson disease (WD). Wilson disease is caused by changes (mutations) in the ATP7B gene that prevent the body from removing excess copper normally. PM577a is designed to precisely correct one of the most common disease-causing ATP7B mutations (p.H1069Q) in liver cells with the goal of restoring normal copper metabolism. This is the first study of PM577a in people. Participants will receive a single intravenous (IV) infusion of PM577a and will be monitored closely to evaluate safety, how the body responds to treatment, whether copper metabolism improves, and whether treatment may improve signs and symptoms of Wilson disease.
Conditions
- Wilson Disease
- Wilson's Disease
- Wilsons Disease
Interventions
PM577aDrug
PM577a is being evaluated in participants with Wilson disease caused by biallelic pathogenic, likely pathogenic, or suspected pathogenic ATP7B variants, including at least one p.H1069Q allele.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of PM577a. Quantified by frequency and severity of treatment emergent adverse events (TEAEs).Time frame: Post-infusion through Week 48
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Yale New Haven Hospital
New Haven, Connecticut · Not yet recruiting
Northwestern University Division of Gastroenterology and Hepatology
Chicago, Illinois · Not yet recruiting
ARC Texas Liver Institute
San Antonio, Texas · Recruiting
New Zealand Clinical Research (NZCR)
Grafton, Auckland, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.